# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers

> **NCT01688089** · PHASE1 · COMPLETED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 67 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ODM103
- **DRUG:** Placebo
- **DRUG:** Entacapone
- **DRUG:** Levodopa/carbidopa

## Key facts

- **NCT ID:** NCT01688089
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2014-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01688089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01688089, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01688089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*